For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors.

TitleAdvances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors.
Publication TypeJournal Article
Year of Publication2017
AuthorsTosi U, Marnell CS, Chang R, Cho WC, Ting R, Maachani UB, Souweidane MM
JournalInt J Mol Sci
Volume18
Issue2
Date Published2017 Feb 08
ISSN1422-0067
KeywordsAnimals, Blood-Brain Barrier, Brain Neoplasms, Central Nervous System Neoplasms, Clinical Trials as Topic, Drug Carriers, Drug Delivery Systems, Humans, Molecular Imaging, Molecular Targeted Therapy, Treatment Outcome
Abstract

Thanks to the recent advances in the development of chemotherapeutics, the morbidity and mortality of many cancers has decreased significantly. However, compared to oncology in general, the field of neuro-oncology has lagged behind. While new molecularly targeted chemotherapeutics have emerged, the impermeability of the blood-brain barrier (BBB) renders systemic delivery of these clinical agents suboptimal. To circumvent the BBB, novel routes of administration are being applied in the clinic, ranging from intra-arterial infusion and direct infusion into the target tissue (convection enhanced delivery (CED)) to the use of focused ultrasound to temporarily disrupt the BBB. However, the current system depends on a "wait-and-see" approach, whereby drug delivery is deemed successful only when a specific clinical outcome is observed. The shortcomings of this approach are evident, as a failed delivery that needs immediate refinement cannot be observed and corrected. In response to this problem, new theranostic agents, compounds with both imaging and therapeutic potential, are being developed, paving the way for improved and monitored delivery to central nervous system (CNS) malignancies. In this review, we focus on the advances and the challenges to improve early cancer detection, selection of targeted therapy, and evaluation of therapeutic efficacy, brought forth by the development of these new agents.

DOI10.3390/ijms18020351
Alternate JournalInt J Mol Sci
PubMed ID28208698
PubMed Central IDPMC5343886